Search Within

Nursing

Formats
  1. Journal Article (1747)
  2. Meeting Abstract (1582)
  3. Book Section (130)
  4. Review (109)
  5. Editorial (92)
  6. Conference Paper (27)
  7. Research Letter (17)
  8. Book Whole (15)
  9. Miscellaneous (15)
  10. Correspondence (12)
  11. Guidelines (10)
Groups
  1. Department of Medicine (1497)
  2. Advanced Practice Providers (1172)
  3. Survivorship Research (962)
  4. Solid Tumor Oncology Division (884)
  5. Epidemiology and Biostatistics (641)
  6. Hematologic Malignancies, Division of (611)

More Groups

People
  1. William Rosa (235)
  2. Nessa Coyle (123)
  3. Sergio Giralt (117)
  4. Mark Kris (114)
  5. Howard Scher (100)
  6. Andrew Zelenetz (99)

More People

Years
  1. 2026 (7)
  2. 2025 (184)
  3. 2024 (213)
  4. 2023 (195)
  5. 2022 (202)
  6. 2021 (171)

More Years

Publications
  1. Journal of Clinical Oncology (451)
  2. Oncology Nursing Forum (420)
  3. Blood (212)
  4. Clinical Journal of Oncology Nursing (121)
  5. Biology of Blood and Marrow Transplantation (88)
  6. Clinical Cancer Research (71)

More Publications

Publishers
  1. Oncology Nursing Society (ONS) (566)
  2. American Society of Clinical Oncology (492)
  3. Elsevier Inc. (428)
  4. Lippincott Williams & Wilkins (260)
  5. American Society of Hematology (226)
  6. American Association for Cancer Research (158)

More Publishers

Results (3756)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma
    Meeting Abstract

    Gounder, M. M.; Dickson, M. A.; Wu, N.; Ivy, S. P.; Carvajal, R. D.; D'Angelo, S. P.; Keohan, M. L.; Qin, L. X.; Erinjeri, J. P.; Takebe, N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis
    Meeting Abstract

    George, C. P.; Luke, J. J.; Winkelman, J.; Cao, Y. T. K. H.; Shakes, L.; Donnelly, K.; Darby, C. H.; Davis, T. W.; Elfring, G. L.; Schwartz, G. K.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Feasibility of screening hospitalized cancer patients for palliative care
    Meeting Abstract

    Glare, P. A.; Plakovic, M. K.; Schloms, A.; Egan, B.; Saltz, L.; Kelsen, D. P.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts)
    Meeting Abstract

    Feldman, D. R.; Voss, M. H.; Jia, X.; Van Alstine, L. J.; Patil, S.; Fischer, P.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M. A.; Keohan, M. L.; Tap, W. D.; Antonescu, C.; Landa, J.; Qin, L. X.; Dohrenwend, E. G.; Rathbone, D.; Ustoyev, Y.; Condy, M. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma
    Meeting Abstract

    Carvajal, R. D.; Ambrosini, G.; Wolchok, J. D.; Chapman, P. B.; Dickson, M. A.; D'Angelo, S. P.; Bluth, M. J.; Paucar, D.; Fusco, A.; Bohr, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade
    Meeting Abstract

    Callahan, M.; Masters, G.; Katz, J.; Russell, V.; Roman, R. A.; Montefusco, M.; Vyas, S.; Yuan, J.; Merghoub, T.; Gupta, A. K.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer
    Meeting Abstract

    Cercek, A.; Shia, J. R.; Gollub, M.; Raasch, P. J.; Hollywood, E.; Reidy, D. L.; Janjigian, Y. Y.; Stadler, Z. K.; Segal, N. H.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save